- Predictive diagnosis of HER2 in gastric adenocarcinomas2011 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- The importance of dual HER2 blockade in early HER2-positive breast cancer2023 | First Faculty of Medicine
- Experience in the treatment of advanced HER2 positive breast tumor in University Hospital in Motol2016 | Publication without faculty affiliation
- Is there a benefit of HER2-positive breast cancer subtype determination in clinical practice?2019 | First Faculty of Medicine, Third Faculty of Medicine
- Complete and long-term response of HER2 positive locally highly advanced metastatic breast cancer - case report2019 | Third Faculty of Medicine
- Trastuzumab deruxtecan: strong player in the field of metastatic HER2 positive breast cancer2022 | First Faculty of Medicine
- Management of HER2-positive breast cancer, escalation and de-escalation of the therapy2017 | First Faculty of Medicine
- Targeted therapy in HER2-positive breast cancer2013 | Faculty of Medicine in Hradec Králové
- Impact of BOLERO-2 study results on clinical practice and future treatment of postmenopausal patients with advance HR+/HER2- breast cancer2014 | First Faculty of Medicine
- The current location of trastuzumab in the treatment of HER2 positive breast cancer2009 | First Faculty of Medicine
- Targeted biological treatment of solid tumors. Controversy treatment HER2 dependent breast cancer2009 | First Faculty of Medicine
- New agent to enhance targeted therapy of metastatic HER2+ breast cancer - pertuzumab2013 | First Faculty of Medicine
- Kdy budou HER2 dependentní karcinomy prsu vyléčitelným onemocněním?2016 | First Faculty of Medicine
- Activity of fulvestrant in HER2-overexpressing advanced breast cancer2010 | First Faculty of Medicine
- Terapie časného HER2 pozitivního karcinomu prsu2022 | Publication without faculty affiliation
- Palbociclib as one of the CDK4/6 inhibitors is of undisputed importance to women with advanced HR+/HER2- breast cancer2019 | Faculty of Medicine in Pilsen
- Metastatic HER2-positive breast cancer - a new standard of treatment2015 | First Faculty of Medicine
- Trastuzumab deruxtecan as standard of care for second-line treatment of metastatic HER2-positive breast cancer2023 | First Faculty of Medicine
- První a druhá linie léčby metastatického HER2 pozitivního karcinomu prsu2017 | First Faculty of Medicine
- Research Report University Hospital for clinical assessment PUMA-NER-1301Publication without faculty affiliation
- Strategies for managing endocrine resistance in advanced hormone receptor-positive and HER2-negative breast cancer2017 | First Faculty of Medicine
- FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer2009 | Third Faculty of Medicine
- The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression2019 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- News in anti-HER2 targeted therapy in breast cancer2013 | First Faculty of Medicine
- Adjuvantní a neoadjuvantní léčba časného HER pozitivního karcinomu prsu. Specifika léčby HER2 pozitivního / HR pozitivního karcinomu prsu2022 | Publication without faculty affiliation
- Eskalace a deeskalace léčby u časného karcinomu prsu s HER2 pozitivitou2021 | First Faculty of Medicine
- Predictive diagnosis in breast cancer - What's new in 2018?2018 | Faculty of Medicine in Hradec Králové
- HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine, Second Faculty of Medicine
- Selective Disruption of Respiratory Supercomplexes as a New Strategy to Suppress Her2(high) Breast Cancer2017 | Publication without faculty affiliation
- Neratinib in the context of an early breast cancer anti-HER2 therapy2020 | First Faculty of Medicine